Key statistics
As of last trade, Evotec SE (EVT:FRA) traded at 5.72, 14.40% above the 52 week low of 5.00 set on Dec 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.66 |
|---|---|
| High | 5.72 |
| Low | 5.66 |
| Bid | 5.70 |
| Offer | 5.74 |
| Previous close | 5.84 |
| Average volume | 51.55k |
|---|---|
| Shares outstanding | 177.88m |
| Free float | 160.14m |
| P/E (TTM) | -- |
| Market cap | 1.05bn EUR |
| EPS (TTM) | -0.8955 EUR |
Data delayed at least 15 minutes, as of Mar 02 2026 11:30 GMT.
More ▼
Announcements
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Disposal of 3653 shares (Sell-to-cover)
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Acquisition of 6760 shares due to vesting (Share Performance Plan 2017)
- EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
More ▼
